{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:37:47Z","timestamp":1782513467512,"version":"3.54.5"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T00:00:00Z","timestamp":1215993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Numerous studies have shown that MDR1 polymorphisms in the form of single nucleotide poymorphisms or haplptype affect ciclosporin pharmacokinetics or blood concentrations in organ transplantation patients, but some results conflict with others.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003We had thought that the diease condition might conceal the minor effect of MDR1 polymorphisms.<\/jats:p><jats:p>\u2022\u2003We chose myasthenia gravis patients as a population in which disease conditions were less severe.<\/jats:p><jats:p>\u2022\u2003We also used different pharmacokinetics indices, such as dose\u2010adjusted trough blood concentrations, dose\u2010adjusted peak blood concentrations and trough blood concentrations under the same ciclosporin regimen.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold>Ciclosporin (CsA), which is widely used in autoimmune disease and transplantation, has a narrow therapeutic index. It also shows considerable interindividual variability in its pharmacokinetics, which may be attributable to polymorphisms of the multidrug efflux pump P\u2010glycoprotein, encoded by MDR\u20101. The aim was to determine the role of genetic polymorphisms in MDR\u20101 with respect to interindividual variability of CsA blood concentrations in myasthenia gravis (MG) patients.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold>MG patients (<jats:italic>n<\/jats:italic>\u2003=\u2003129) receiving CsA were genotyped for MDR\u20101 1236C\u2192T (exon 12), 2677G\u2192T (exon 21) and 3435C\u2192T (exon 26). Trough blood and peak blood concentrations were determined to see if there was correlation with the corresponding genotype.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>We observed a trend for CsA blood concentrations, especially peak blood concentrations, to be higher with the wild\u2010type allele compared with minor alleles in genotype and haplotype. Furthermore, under the same CsA regimen, it was found that the trough concentrations of variant genotype (ABCB1 1236TT or ABCB1 2677TT) were significant greater than those of wild\u2010type (ABCB1 1236CC or ABCB1 2677GG, respectively) (<jats:italic>P<\/jats:italic>\u2003=\u20030.0222 and 0.0081). The trough concentrations of wild\u2010type haplotype pair group were significantly lower those that of the mutant type pair group (TT\u2010TT\u2010TT) (<jats:italic>P<\/jats:italic>\u2003=\u20030.007).<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold>ABCB1 polymorphisms in both genotype and haplotype may have a minor effect on the CsA blood concentrations.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2008.03180.x","type":"journal-article","created":{"date-parts":[[2008,7,14]],"date-time":"2008-07-14T11:06:14Z","timestamp":1216033574000},"page":"240-246","source":"Crossref","is-referenced-by-count":22,"title":["ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients"],"prefix":"10.1111","volume":"66","author":[{"given":"Ya\u2010tong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke\u2010xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun\u2010hua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u2010wen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28923"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.20814.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53221-X"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(02)00297-4"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90027-8"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3473"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200208000-00002"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0022-3565(24)29643-9","article-title":"Expression of P\u2010glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)\u20101 gene","volume":"297","author":"Tanabe M","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/23.5.881"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200208000-00004"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.129196"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5439.487"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01820.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.117412"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000073901.94759.36"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01820.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.129196"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03180.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03180.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:46:12Z","timestamp":1738284372000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03180.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,14]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03180.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03180.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,14]]}}}